West Pharmaceutical ServicesKPI data tables
West Pharmaceutical Services operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | GLP-1 elastomers | GLP-1 West Vantage / CM | Printed total |
|---|---|---|---|
| Q2 2026 | 10 | 8 | 18 |
| Q1 2026 | 10 | 8 | 18 |
| Q4 2025 | 10 | 7 | 17 |
| Q3 2025 | 9 | 8 | 17 |
Source: West Pharmaceutical Services earnings presentation, growth-drivers slide. Q3 2025 elastomers 9%, contract manufacturing 8%, combined 17%: https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/a3q25earningspresentatio.htm. Q4 2025 elastomers 10%, contract manufacturing 7%, combined 17%: https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/a4q25earningsdeck-final.htm. Q1 2026 elastomers 10%, West Vantage 8%, combined 18%: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/a1q26earningsdeck-final.htm. Q2 2026 elastomers 10%, West Vantage 8%, combined 18%: https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/a2q26earningsdeck-final.htm.
| Period | HVP Components organic growth (%) |
|---|---|
| Q3 2026 | 20.3 |
| Q2 2026 | 18.4 |
| Q1 2026 | 22.6 |
| Q4 2025 | 15.1 |
| Q3 2025 | 13.3 |
Source: West Pharmaceutical Services Form 8-K Exhibit 99.1, Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category, Organic Net Sales Growth Rate (Decline) column for HVP Components (three-month only; not H1/YTD/FY; not Proprietary Products or company organic; not GLP-1 share). Later filing wins. Q3 2025 https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/exh991q32025earningsrelease.htm; Q4 2025 https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/exh991q42025earningsrelease.htm; Q1 2026 https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/exh991q12026earningsrelease.htm; Q2 2026 https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/exh991q22026earningsrelease.htm; Q3 2026 https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/exh991q32026earningsrelease.htm.
| Period | Americas | Europe, Middle East, Africa | Asia Pacific |
|---|---|---|---|
| Q3 2026 | 401.3 | 376.1 | 97.1 |
| Q2 2026 | 388.7 | 399.8 | 83.8 |
| Q1 2026 | 377.3 | 399.4 | 68.2 |
| Q4 2025 | 358.6 | 370.2 | 76.2 |
| Q3 2025 | 375.3 | 361.1 | 68.2 |
| Q2 2025 | 349.7 | 349.7 | 67.1 |
| Q1 2025 | 338.9 | 306.9 | 52.2 |
Source: West Pharmaceutical Services Form 8-K Exhibit 99.1, Reconciliation of Reported Net Sales to Organic Net Sales by Geography. Q2 2026 and Q2 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/exh991q22026earningsrelease.htm. Q1 2026 and Q1 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/exh991q12026earningsrelease.htm. Q4 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/exh991q42025earningsrelease.htm. Q3 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/exh991q32025earningsrelease.htm. Q3 2026: https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/exh991q32026earningsrelease.htm.
| Period | HVP Components | HVP Delivery Devices | Standard Products |
|---|---|---|---|
| Q3 2026 | 466.7 | 99.1 | 163 |
| Q2 2026 | 424.1 | 131.2 | 167.3 |
| Q1 2026 | 409.3 | 123.6 | 161.4 |
| Q4 2025 | 389.8 | 110.4 | 161.6 |
| Q3 2025 | 390 | 99.1 | 158.4 |
| Q2 2025 | 355.2 | 101.2 | 163.4 |
| Q1 2025 | 315.9 | 95.8 | 151.3 |
Source: West Pharmaceutical Services Form 8-K Exhibit 99.1, Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category. Q2 2026 and Q2 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/exh991q22026earningsrelease.htm. Q1 2026 and Q1 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/exh991q12026earningsrelease.htm. Q4 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/exh991q42025earningsrelease.htm. Q3 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/exh991q32025earningsrelease.htm. Q3 2026: https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/exh991q32026earningsrelease.htm.
| Period | Biologics | Pharma | Generics |
|---|---|---|---|
| Q3 2026 | 379.3 | 221.3 | 128.2 |
| Q2 2026 | 374.8 | 205 | 142.8 |
| Q1 2026 | 354.5 | 210.6 | 129.2 |
| Q4 2025 | 340.4 | 191.5 | 129.9 |
| Q3 2025 | 329.1 | 182.5 | 135.9 |
| Q2 2025 | 287.7 | 198.5 | 133.6 |
| Q1 2025 | 269.3 | 180.6 | 113.1 |
Source: West Pharmaceutical Services Form 8-K Exhibit 99.1, Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group. Q2 2026 and Q2 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/exh991q22026earningsrelease.htm. Q1 2026 and Q1 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/exh991q12026earningsrelease.htm. Q4 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/exh991q42025earningsrelease.htm. Q3 2025: https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/exh991q32025earningsrelease.htm. Q3 2026: https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/exh991q32026earningsrelease.htm.